- Global Pharma News & Resources

European Patent Granted for Sareum’s SDC-1802, a Novel Small Molecule TYK2/JAK1 Inhibitor, for the Treatment of T-cell Acute Lymphoblastic Leukaemia

Cambridge, UK, 11 April 2022 – Sareum Holdings plc (AIM: SAR), the specialist drug development company, announces that, further to its announcement on 15 December 2021, the European Patent Office has now issued a formal notification of grant for a patent in respect of an invention associated with Sareum’s proprietary SDC-1802 TYK2/JAK1 inhibitor programme. The patent will come into effect on 4 May 2022.

The patent (EPO Patent no. EP3528806) will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat T-cell acute lymphoblastic leukaemia (T-ALL – a cancer of a particular type of white blood cell called a T lymphocyte) and other cancers that are dependent on TYK2 kinase for survival. This programme is in preclinical development.

Sareum’s CSO, Dr John Reader, commented:

“This newly issued European patent for SDC-1802 expands our already broad and robust patent portfolio covering both our novel TYK2/JAK1 inhibitor candidates and further supports their commercial potential as new treatments for autoimmune diseases and cancer. Building a strong intellectual property portfolio around our TYK2/JAK1 assets is a core strategic focus for Sareum that we believe is creating important value for our shareholders.”

Editor Details

  • Name:
    • Tim Mitchell
Last Updated: 12-Apr-2022